Abstract
Previous research has shown that immune development during the first week of life, i.e. ontogeny, is progressive, consistent and robust, involving large numbers of differentially expressed genes at each sampled time point. To obtain more granular detail about conserved and population-specific ontogeny, the influence of day of life on blood gene expression and cell type composition was examined in two distinct neonatal populations, from The Gambia and Papua New Guinea, employing block randomization strategies to minimize batch effects. This enabled more detailed conclusions about ontogenic program differences between the two cohorts. Population-specific ontogeny revealed mechanistic insights likely to contribute to inherent population-based heterogeneity in the efficiency of neonatal immune responses, including cell cycle, kinesins, and DAP12 signaling in Papua New Guinea, and antigen presentation, clathrin-mediated endocytosis and alpha-defensins in The Gambia. Differences between populations interconnect using protein:protein interaction networks of population-specific genes and pathinkR-based pathway networks and heat maps, thus fitting the concept of pathway/network remodeling. In addition to the population-specific changes, there is a profound core ontogenic gene-expression program involving ~18% of all expressed genes with remarkable 88-96% conservation at each day of life, revealing new contributors to this shared early-life ontogenic program.
Acknowledgments
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Human Immunology Project Consortium (HIPC) Award Number U19AI118608. REWH was further supported by the Canadian Institutes for Health Research FDN-154287 and is the recipient of a UBC Killam professorship. AA, JDA, KKS and OL were also supported in part by an NIH/NIAID Immune Development in Early Life grant (IDEAL; U19AI168643). AA was supported in part by a Mentored Clinical Scientist Development Award (K08AI168487). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding
Funding from the Canadian Institutes for Health Research (CIHR) FDN-154287 to RH is gratefully acknowledged. RH holds a UBC Killam Professorship. TB and AHL are supported by the Canadian Institutes for Health Research [PJT-183926]. AHL was also supported by the Michael Smith Health Research BC Scholar Award.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
OL is co-founder of ARMR Sciences (formerly Ovax, Inc), a company that develops protective therapeutics against opioid overdose. He is a named inventor on patents held by Boston Children’s Hospital relating to human in vitro model systems and small molecule adjuvants. He is a consultant to and receives sponsored research support from GlaxoSmithKline (GSK). The remaining authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Dhillon, B.K., Blimkie, T.M., Idoko, O.T. et al. Population-specific heterogeneity in ontogeny of the broadly-conserved blood transcriptional program during the first week of life. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73244-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-026-73244-4